Question 1

What is OpenEvidence and how does it work for physicians?

Accepted Answer

OpenEvidence is an AI-powered clinical decision support platform that physicians use to answer clinical questions in real time — at the point of care, while seeing patients, or during documentation. The product ingests and synthesizes medical literature, clinical guidelines, drug interactions, and real-world outcomes data to provide evidence-backed answers to questions like 'What is the first-line treatment for this presentation in a patient with these comorbidities?' Unlike general-purpose AI assistants, OpenEvidence is trained on and indexed against the current medical literature and designed to cite its sources transparently — a critical trust requirement in a domain where a wrong answer can harm patients. The product operates in the clinical documentation assistance category, which means it supports physician decision-making and documentation workflows rather than making autonomous diagnostic or prescribing decisions. This positioning keeps it out of the FDA regulatory pathway that would otherwise create a multi-year barrier to market entry. As of early 2026, more than 757,000 verified physicians have signed up for the platform, and the company reports over 40% of U.S. physicians use it regularly.

Question 2

How did OpenEvidence grow to reach 40% of U.S. physicians?

Accepted Answer

OpenEvidence's growth trajectory is exceptional even by AI-era standards. The company grew monthly clinical consultations from approximately 3 million per month in late 2024 to 18 million per month in December 2025 — a 6x increase in 12 months. That growth was driven by three interconnected mechanisms. First, physician peer networks: physicians are a highly connected professional community that relies heavily on collegial recommendations. When a physician finds a tool that genuinely saves time and improves accuracy in a workflow they perform dozens of times daily, they share it with peers at rounds, conferences, and in department channels. The peer recommendation flywheel in medicine is more powerful than in almost any other professional category. Second, hospital system integrations: OpenEvidence secured partnerships and EHR integrations that brought the product into clinical workflows through the institution rather than requiring individual physician signups. Third, the free tier for individual physicians created zero-friction adoption that allowed the peer flywheel to operate without financial barriers at the individual level. Revenue comes from enterprise hospital contracts and institutional licenses, not from charging individual physicians — a GTM structure that maximizes adoption speed while monetizing through the procurement channel most appropriate for healthcare enterprise sales.

Question 3

Why is clinical documentation AI different from diagnostic AI for regulatory purposes?

Accepted Answer

The FDA regulates AI as a medical device when it is intended to diagnose, treat, cure, or prevent disease — a definition that applies to AI that provides diagnostic conclusions, recommends specific treatments, or interprets medical images for diagnostic purposes. Clinical documentation and decision support tools that assist physicians without making autonomous clinical decisions fall outside the primary medical device regulatory pathway under the current FDA framework, though this regulatory landscape is evolving. OpenEvidence is designed and positioned as a documentation assistance and evidence synthesis tool: it gives physicians access to synthesized medical literature and surfaces relevant evidence for the physician to apply using their own clinical judgment. The physician makes the clinical decision; OpenEvidence provides the evidentiary context. This positioning is deliberate and has allowed OpenEvidence to reach market and scale without the 18- to 36-month FDA clearance timelines that diagnostic AI companies face. The clinical documentation market is also, practically speaking, enormous: U.S. physicians spend an average of 2.6 hours per day on documentation, and reducing that burden has measurable impact on physician burnout, patient throughput, and system cost without requiring the regulatory approval needed for clinical decision-making AI.

Question 4

What makes OpenEvidence's GTM strategy different from other healthcare AI companies?

Accepted Answer

Most healthcare AI companies in 2024 and 2025 attempted to sell top-down into hospital systems — approaching CIOs, CMOs, and procurement committees with enterprise contracts, multi-month pilots, and committee approvals. OpenEvidence inverted this model. It launched with a free tier for individual physicians, optimized the product for speed and accuracy to the point where it was genuinely faster and more reliable than manual literature searches, and let physician peer networks do the distribution work. By the time hospital procurement committees were evaluating enterprise contracts, OpenEvidence had already achieved organic adoption rates of 30 to 40 percent within those hospitals. The enterprise sale became a formalization of existing behavior rather than a behavior change initiative — one of the most favorable sales dynamics in enterprise software. This bottom-up penetration strategy requires accepting low revenue per physician during the growth phase, which explains why OpenEvidence needed venture capital backing at a significant scale. But it eliminates the primary obstacle that kills healthcare AI startups: the years-long gap between regulatory clearance, hospital IT integration approval, clinical champion identification, and actual physician adoption. OpenEvidence short-circuited all of those obstacles by making the individual physician experience exceptional before worrying about institutional contracts.

Question 5

What is the vertical AI dominance playbook that OpenEvidence demonstrates?

Accepted Answer

OpenEvidence's growth illustrates a repeatable vertical AI dominance playbook that applies across professional services categories where expert judgment is central. The six principles are: First, find the workflow that is simultaneously the most painful and the most frequent — for physicians, clinical literature search and documentation were both. Second, build for the expert, not the institution — physicians evaluate tools by accuracy and speed, not by vendor pedigree. Third, position in the regulatory safe lane — clinical documentation does not require FDA approval, while diagnostic AI does. Fourth, use the free individual tier as a distribution channel, with institutional contracts as the monetization layer. Fifth, invest in accuracy and citation transparency above all other product features — in high-stakes professional domains, trust is the moat. Sixth, build EHR integrations early to embed into the institutional workflow before competitors can match your adoption numbers. Each of these principles is domain-specific in its implementation but domain-agnostic in its logic — the same framework applies to legal AI (Clio, Harvey), financial services AI (BloombergGPT applications), and accounting AI (various QuickBooks AI integrations). The common thread is using a genuinely superior individual user experience to establish adoption before competitors can engage institutional procurement.